← Leaderboards
Gregory M Lanza
Barnes-Jewish Hospital
$17,053,599
Attributed
$24,228,577
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$35,728,646 · 16
By mechanism
U54$16,654,558 · 5
R01$15,312,611 · 8
R42$3,034,096 · 2
N01$727,381 · 1
Top collaborators
- Samuel Achilefu13 shared
- Katherine Nelson Weilbaecher10 shared
- Dipanjan Pan5 shared
- Elizabeth Wagner5 shared
- Y Andrew Wang4 shared
- James Blackledge3 shared
Others in their field
Top investigators on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$332,241,999
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$217,904,052
- Ethan Schreier · Associated Universities, Inc.$206,468,864
Research focus
ImageNanoparticleNanomedicineResponseBaseProgramsPharmaceutical PreparationsResearch PersonnelTechnologyProdrugsIn VivoDrug Delivery SystemsCessation Of LifeDoseMalignant NeoplasmsDrug KineticsChemotherapyAcuteNanotherapyMolecular ImagingToxic EffectDiagnosisNeoplasm MetastasisInnovation
Grant awards (59)
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$610,502
R01 · FY2022 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2021 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2020 · CA · contact PI
Center for Multiple Myeloma Nanotherapy$2,096,597
U54 · FY2019 · CA
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$728,200
R42 · FY2019 · HL
Project 1 - Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with CMYC-MAX Nanoparticles$672,844
U54 · FY2019 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$604,272
R01 · FY2019 · CA · contact PI
Center for Multiple Myeloma Nanotherapy$392,504
U54 · FY2019 · CA
Center for Multiple Myeloma Nanotherapy$2,184,301
U54 · FY2018 · CA
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$768,622
R42 · FY2018 · HL
Project 1 - Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with CMYC-MAX Nanoparticles$693,840
U54 · FY2018 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2018 · CA · contact PI
DIAGNOSIS OF LEFT VENTRICULAR ASSIST DEVICE INTRAPUMP THROMBOSIS$426,857
R01 · FY2018 · HL · contact PI
Center for Multiple Myeloma Nanotherapy$2,224,884
U54 · FY2017 · CA
Project 1 - Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with CMYC-MAX Nanoparticles$694,166
U54 · FY2017 · CA · contact PI
DIAGNOSIS OF LEFT VENTRICULAR ASSIST DEVICE INTRAPUMP THROMBOSIS$423,349
R01 · FY2017 · HL · contact PI
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events$151,903
R42 · FY2017 · HL
Center for Multiple Myeloma Nanotherapy$29,864
U54 · FY2017 · CA
Center for Multiple Myeloma Nanotherapy$2,230,648
U54 · FY2016 · CA
Project 1 - Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with CMYC-MAX Nanoparticles$701,318
U54 · FY2016 · CA · contact PI
Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine$673,514
R01 · FY2016 · HL · contact PI
DIAGNOSIS OF LEFT VENTRICULAR ASSIST DEVICE INTRAPUMP THROMBOSIS$423,349
R01 · FY2016 · HL · contact PI
Center for Multiple Myeloma Nanotherapy$57,523
U54 · FY2016 · CA
Center for Multiple Myeloma Nanotherapy$27,659
U54 · FY2016 · CA
Center for Multiple Myeloma Nanotherapy$2,256,089
U54 · FY2015 · CA
Project 1 - Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with CMYC-MAX Nanoparticles$708,796
U54 · FY2015 · CA · contact PI
Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine$663,410
R01 · FY2015 · HL · contact PI
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor$492,514
R42 · FY2015 · HL
DIAGNOSIS OF LEFT VENTRICULAR ASSIST DEVICE INTRAPUMP THROMBOSIS$484,793
R01 · FY2015 · HL · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$482,398
R01 · FY2015 · CA · contact PI
Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine$660,044
R01 · FY2014 · HL · contact PI
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor$500,010
R42 · FY2014 · HL
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$469,056
R01 · FY2014 · CA · contact PI
Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine$641,184
R01 · FY2013 · HL · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$455,665
R01 · FY2013 · CA · contact PI
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor$193,077
R42 · FY2013 · HL
Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine$662,009
R01 · FY2012 · HL · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$485,959
R01 · FY2012 · CA · contact PI
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor$199,770
R42 · FY2012 · HL
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$487,193
R01 · FY2011 · CA · contact PI
Fibrin-Specific Thrombolytic Nanoparticles for Acute Stroke$325,850
R01 · FY2011 · NS · contact PI
COLLOIDAL IRON-OXIDE NANOBEACONS FOR THERANOSTIC USE IN ATHEROSCLEROSIS$710,188
R01 · FY2010 · HL · contact PI
Fibrin-Specific Thrombolytic Nanoparticles for Acute Stroke$329,176
R01 · FY2010 · NS · contact PI
COLLOIDAL IRON-OXIDE NANOBEACONS FOR THERANOSTIC USE IN ATHEROSCLEROSIS$705,598
R01 · FY2009 · HL · contact PI
Neovascular-Direct Nanoparticles for Detection, Characterization, and Treatment$524,194
U54 · FY2009 · CA · contact PI
Fibrin-Specific Thrombolytic Nanoparticles for Acute Stroke$332,500
R01 · FY2009 · NS · contact PI
Biosignature and Vector Development Core$309,867
U54 · FY2009 · CA · contact PI
Task Specific Project 2: Perfluorocarbon Nanoparticles$152,044
U54 · FY2009 · CA · contact PI
Neovascular-Direct Nanoparticles for Detection, Characterization, and Treatment$358,400
U54 · FY2008 · CA · contact PI
Fibrin-Specific Thrombolytic Nanoparticles for Acute Stroke$332,500
R01 · FY2008 · NS · contact PI
Biosignature and Vector Development Core$232,905
U54 · FY2008 · CA · contact PI
Task Specific Project 2: Perfluorocarbon Nanoparticles$106,115
U54 · FY2008 · CA · contact PI
Combined Therapeutic-Imaging Agent for Atherosclerosis$362,679
R01 · FY2007 · HL · contact PI
Fibrin-Specific Thrombolytic Nanoparticles for Acute Stroke$332,591
R01 · FY2007 · NS · contact PI
Molecular Imaging of Angiogenesis by MRI$228,487
R01 · FY2007 · EB · contact PI
Combined Therapeutic-Imaging Agent for Atherosclerosis$370,924
R01 · FY2006 · HL · contact PI
Combined Therapeutic-Imaging Agent for Atherosclerosis$379,850
R01 · FY2005 · HL
Combined Therapeutic-Imaging Agent for Atherosclerosis$379,831
R01 · FY2004 · HL
NOVEL TECHNOLOGIES FOR NONINVASIVE DETECTION, DIAGNOSIS$727,381
N01 · FY2000 · CO